Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
Aude De GassartKieu-Suong LePatrick BruneSophie AgauguéJennifer SimsArmelle GoubardRémy CastellanoNoémie JoallandEmmanuel ScotetYves ColletteEmmanuel ValentinClement GhigoChristine PaseroMagali ColazetJaime GuillénCarla E CanoAurélien MarabelleJohann S de BonoRené HoetAlemseged TrunehDaniel OlivePaul A FrohnaPublished in: Science translational medicine (2021)
[Figure: see text].